Nasdaq pgen.

Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target urgent ...Precigen (NASDAQ: PGEN) is not a big biotech company. Its market capitalization is just $277 million. Its market capitalization is just $277 million. However, it’s got an interesting history.Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...Jan 11, 2023 · Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ... (NASDAQ: PGEN) Precigen's 52-week high was $2.29, and its 52-week low was $0.81. It is currently -49.3% from its 52-week high and 44.1% from its 52-week low. …

While institutions own 26% of Precigen, Inc. (NASDAQ:PGEN), private equity firms are its largest shareholders with 37% ownership.(NASDAQ: PGEN) Precigen currently has 248,919,096 outstanding shares. With Precigen stock trading at $1.16 per share, the total value of Precigen stock (market capitalization) is $288.75M . Precigen stock was originally listed at a price of $24.73 in Aug 8, 2013 .

Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target urgent ...

Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...Precigen (NASDAQ: PGEN) $1.26 (-3.8%) -$0.05 Price as of November 8, 2023, 4:00 p.m. ET Key Data Points Current Price $1.26 Daily Change (-3.8%) -$0.05 Day's Range $1.21 - $1.31 Previous Close...Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...Precigen Inc (PGEN). NASDAQ. 1.130 -0.030 -2.59 ...Precigen (NASDAQ: PGEN) is not a big biotech company. Its market capitalization is just $277 million. Its market capitalization is just $277 million. However, it’s got an interesting history.

Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...

Find the latest Institutional Holdings data for Precigen, Inc. Common Stock (PGEN) at Nasdaq.com.

In January 2023, four company executives bought PGEN stock. The largest of those buys was from executive chairman (and former CEO) Randall Kirk. Kirk purchased 11,428,571 shares of PGEN stock for ...Who is on Precigen's Insider Roster? The list of insiders at Precigen includes Dean J Mitchell, Donald P Lehr, Harry Jr. Thomasian, Helen Sabzevari, Jeffrey B Kindler, Jeffrey Thomas Perez, Randal J Kirk, Rick L Sterling, Rutul R Shah, Steven Frank, and Trading S.A. Ares. Learn more on insiders at PGEN.Back to PGEN Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.Nov 29, 2023 · Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ... Precigen (Nasdaq: PGEN) is a biopharmaceutical company advancing the next generation of gene and cell therapies. | Precigen: Advancing Medicine with Precision™ Precigen (Nasdaq: PGEN) is a ...

PGEN : 1.0100 (-7.34%) Precigen, Inc. (PGEN) Moves to Buy: Rationale Behind the Upgrade Zacks - Fri Jan 27, 11:00AM CST. Precigen, Inc. (PGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. (NASDAQ: EXFY) filed a lawsuit in the U.S. District Court for the District of Oregon over alleged violations of Federal Securities Laws by… 01/22/2024. Veradigm ...Precigen, Inc. (PGEN) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. 2W 10W 9M. 1.1900 +0.0700 (+6.25%) At close: 04:00PM EST. 1.1900 0.00 (0.00%) After hours: 04:41PM EST. View real-time PGEN stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ...Fiscal Q3 2023 ended 9/30/23. Get the latest Precigen Inc (PGEN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and ... In 2023, Precigen (NASDAQ: PGEN), a clinical-stage company, is garnering high expectations from Wall Street analysts. The average price target is $8.77 on last look, translating into over 618% upside.

Precigen, Inc. (Nasdaq: PGEN) - A settlement was reached in the class action against Precigen, Inc. in which a settlement fund of $13,000,000 was created for the benefit of class members.

Precigen (NASDAQ:PGEN), a Virginia-based biopharmaceutical company, focuses on advancing gene and cell therapies to improve patient outcomes for unmet medical needs. The company uses proprietary ...Nasdaq Futures. 15511.25-27.25 (-0.18%). Dow Jones Futures. 34865.0074.00 (0.21 ... NASDAQ:PGEN · Buy Candidate. Precigen, Inc. Stock Price (Quote). NASDAQ Stock ...Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using ...Precigen Announces Pricing of $75.0 Million Public Offering of Common Stock. GERMANTOWN, Md. , Jan. 24, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 42,857,143 shares of its common stock at a public offeri... 11 months ago - PRNewsWire.Precigen Inc. analyst ratings, historical stock prices, earnings estimates & actuals. PGEN updated stock price target summary.What You Need To Know About Precigen, Inc.'s (NASDAQ:PGEN) Investor Composition. Jan 8, 2022. Although most of the market cap awarded to synthetic-biology conglomerate Intrexon (PGEN-0.89%) is derived from its potential in healthcare, analysts are beginning to eye the potential for perhaps ...Aug 28, 2023 · Precigen ( NASDAQ: PGEN) is a clinical-stage biopharmaceutical firm focusing on next-generation gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases ... As of March 2015, Theranos is a private company and does not have a public stock symbol. The medical technology company has a partnership with the public company, Walgreens, which has a stock symbol of WAG on Nasdaq.

Nasdaq | PGEN U.S.: Nasdaq Precigen Inc. Watch list Open Last Updated: Nov 24, 2023 1:00 p.m. EST Delayed quote $ 1.1600 0.0200 1.75% Previous Close $1.1400 Advanced Charting Volume: 960.7K...

View real-time PGEN stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ...

Stock analysis for Precigen Inc (PGEN:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX. Copyright © 2007-2023 FINVIZ.com. All Rights Reserved. Quantcast. × ...Maybe you’ve never invested before. Maybe you have no clue what the difference is between NASDAQ and the New York Stock Exchange. Regardless, the name Charles Schwab probably rings a bell.Look at Axsome Therapeutics (NASDAQ:AXSM), for example. At one time, it was a $2.50 stock. Now it’s up to $71 with a treatment for major depressive disorder. ... Precigen (NASDAQ:PGEN) is ...The small-cap stock on my list is Precigen (NASDAQ: PGEN). The company is developing its UltraCAR-T platform. ... Kirk purchased 11,428,571 shares of PGEN stock for $1.75.Precigen (Nasdaq: PGEN) is a biopharmaceutical company advancing the next generation of gene and cell therapies. | Precigen: Advancing Medicine with Precision™ Precigen (Nasdaq: PGEN) is a ...Precigen (NASDAQ: PGEN) $1.26 (-3.8%) -$0.05 Price as of November 8, 2023, 4:00 p.m. ET Key Data Points Current Price $1.26 Daily Change (-3.8%) -$0.05 Day's Range $1.21 - $1.31 Previous Close...

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today …Intrexon's shares nosedived today on a worse-than-expected third-quarter earnings release.Dec 4, 2023 · Over the past 30 days, the shares of Precigen Inc (NASDAQ:PGEN) have changed 11.21%. Short interest in the company has seen 16.25 million shares shorted with days to cover at 9.69. Wall Street analysts have a consensus price target for the stock at $9.00, which means that the shares’ value could jump 86.78% from current levels. Dividend history information is presently unavailable for this company. This could indicate that the company has never provided a dividend or that a dividend is ...Instagram:https://instagram. luminar stock forecastportfolio pilottfra accountscarter worth stock picks Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ... stock apocoinase stock Precigen Inc (PGEN). NASDAQ. 1.130 -0.030 -2.59 ... how much is 1943 penny worth ... (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision ...Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX. Copyright © 2007-2023 FINVIZ.com. All Rights Reserved. Quantcast. × ...Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most ...